BUZZ - Henry Schein shares fall after appointing new Chief Financial Officer

路透社2026/10/08 11:47

Show original

October 8 - ** Shares of dental products distributor Henry Schein (HSIC.O) dropped 2% to $82 in pre-market trading. ** Ronald South, who has served as CFO for the past four years, will transition to Senior Advisor. ** Emmanuel Caprais will take over as CFO, officially assuming the role on November 4. ** Caprais was previously the Chief Financial Officer of global industrial manufacturer ITT. ** This leadership change comes about seven months after Frederick Lowery succeeded Stanley Bergman as CEO; Bergman had led the company for 35 years. ** Among 18 brokers, 9 rate the stock as “buy” or above, 8 as “hold”, and 1 as “sell”; the median target price is $96—data compiled by LSEG. ** As of the previous trading day's close, the stock has risen 10.69% year-to-date.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 8 - ** Shares of dental product distributor Henry Schein (HSIC.O) fell 2% in pre-market trading to $82

** Ronald South, who has served as chief financial officer for the past four years, will move to the role of senior advisor

** Emmanuel Caprais will take over as chief financial officer, officially assuming the role on November 4

** Caprais previously served as chief financial officer of global industrial manufacturer ITT

** The personnel changes come about seven months after Frederick Lowery replaced Stanley Bergman as chief executive officer; Bergman had led the company for 35 years

** Of 18 brokerages, nine rate the stock as "buy" or higher, eight as "hold", and one as "sell"; the median price target is $96—data compiled by LSEG

** As of the close of the previous trading day, the stock is up 10.69% year to date

(To assist non-native English speakers, Reuters provides automated translation of its reports into several other languages. Because automated translation may contain errors or fail to provide needed context, Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no responsibility for any loss or damage resulting from use of this automated translation feature.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11